Company news

Dianthus Therapeutics, Inc. news in 2024

Dianthus Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

November 3, 2024

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting

October 14, 2024

Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September

September 3, 2024

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)

June 27, 2024

Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)

June 11, 2024

Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 29, 2024

Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference

May 7, 2024

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2024

Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting

April 10, 2024

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results

March 20, 2024

Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 6, 2024

Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)

February 25, 2024

Decks in 2024